Nuvalent NUVL
NUVL
$123.96 +0.00 (+0.00%)
At close: Jul 21, 2026 · 4:00 PM EDT

Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026)

Nuvalent's (NUVL) quarterly Cash from Investing Activities came in at -$19.4 million in Q1 2026, down 176.38% YoY from $25.4 million in Q1 2025, and up 93.09% on a QoQ basis from -$280.9 million in Q4 2025.

Analysis

Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026) Analysis & Trends

Nuvalent (NUVL) has 6 years of Cash from Investing Activities data on file, last reported at -$19.4 million in Q1 2026.

  • Quarterly Cash from Investing Activities fell 176.38% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$168.9 million (up 50.51% YoY) and the FY2025 annual result came in at -$124.1 million, up 78.37% from the prior year.
  • Cash from Investing Activities improved to -$19.4 million in Q1 2026, from -$280.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $77.5 million in Q2 2025 to a low of -$280.9 million in Q4 2025.
  • A 5-year average of -$51.2 million and a median of $1.6 million in 2023 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 1074.65% — and 2024, when it soared 916.81%.
  • Tracing NUVL's Cash from Investing Activities over 5 years: stood at -$65.4 million in 2022, then gained by 13.98% to -$56.3 million in 2023, then slumped by 202.24% to -$170.0 million in 2024, then plunged by 65.22% to -$280.9 million in 2025, then jumped by 93.09% to -$19.4 million in 2026.
  • The last three Cash from Investing Activities figures came in at -$19.4 million (Q1 2026), -$280.9 million (Q4 2025), and $54.0 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Nuvalent 9.75 Bn 9.75 Bn - -19.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -19.41 Mn
Dec 31, 2025 -280.94 Mn
Sep 30, 2025 53.97 Mn
Jun 30, 2025 77.48 Mn
Mar 31, 2025 25.42 Mn
Dec 31, 2024 -170.05 Mn
Sep 30, 2024 -212.91 Mn
Jun 30, 2024 16.21 Mn
Mar 31, 2024 -206.77 Mn
Dec 31, 2023 -56.26 Mn
Sep 30, 2023 38.40 Mn
Jun 30, 2023 1.59 Mn
Mar 31, 2023 -127.26 Mn
Dec 31, 2022 -65.40 Mn
Sep 30, 2022 17.57 Mn
Jun 30, 2022 24.11 Mn
Mar 31, 2022 13.06 Mn
Dec 31, 2021 -163.46 Mn
Sep 30, 2021 -56.57 Mn